| 2025-11-05 |
详情>>
股本变动：
变动后总股本11742.50万股
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.42美元,归母净利润-5045.1万美元,同比去年增长-349.03%
|
| 2025-11-05 |
财报披露：
美东时间 2025-11-05 盘后发布财报
|
| 2025-08-22 |
详情>>
内部人交易：
Myers Scott Dunseth股份增加3800.00股
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.63美元,归母净利润-7737.8万美元,同比去年增长-3003.49%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益-0.77美元,归母净利润-9609.9万美元,同比去年增长-1001.93%
|
| 2025-04-17 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.To elect our four director nominees, Brett A. Erkman, Jeffrey S. Farrow, Michael Mullette and Donald J. Santel (each, a “Deep Track Nominee” and, together, the “Deep Track Nominees”), to the Board as Class I directors for a term of three years, to serve until the 2028 annual meeting of Stockholders (the “2028 Annual Meeting”) and until their respective successors are duly elected and qualified;
2.To vote, on an advisory basis, as to the compensation of the Company’s named executive officers;
3.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for its fiscal year ending December 31, 2025;
4.To approve the Company’s proposal to amend and restate the Company’s Restated Certificate of Incorporation (the “Declassification Restatement”), pursuant to which the Company would phase-in the declassification of the Board over three years, whereby members of the Board standing for election at the 2026 Annual Meeting and thereafter would be elected for annual terms, such that all directors would stand for reelection annually, beginning with the 2028 annual Meeting, and implement certain other changes (such proposed amendment to the Charter, the “Declassification Plan”);
5.To approve our proposal to repeal each provision of, or amendment to, the Company’s Amended and Restated Bylaws (as amended, supplemented or modified from time to time, the “Bylaws”) that the Board adopted without the approval of Stockholders subsequent to November 6, 2018, which is the date of the most recent publicly available amendment to the Bylaws, and up to and including the end of the 2025 Annual Meeting (the “Bylaw Proposal”);
6.To transact such other business as may properly come before the 2025 Annual Meeting or any adjournment(s) thereof.
|
| 2025-02-20 |
详情>>
业绩披露：
2022年年报每股收益2.32美元,归母净利润2.93亿美元,同比去年增长305.96%
|
| 2025-02-20 |
详情>>
业绩披露：
2024年年报每股收益0.21美元,归母净利润2730.90万美元,同比去年增长527.44%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.15美元,归母净利润2025.90万美元,同比去年增长406.58%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益-0.16美元,归母净利润-2090.1万美元,同比去年增长-112.93%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益0.02美元,归母净利润266.50万美元,同比去年增长112.75%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.07美元,归母净利润-872.1万美元,同比去年增长64.16%
|
| 2024-04-11 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect our three nominees for Class III directors to hold office until the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve the amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 11,400,000.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement accompanying this Notice.
4.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益-0.05美元,归母净利润-638.9万美元,同比去年增长-102.18%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.05美元,归母净利润-660.8万美元,同比去年增长-102.93%
|
| 2023-04-13 |
股东大会：
将于2023-05-26召开股东大会
会议内容 ▼▲
- 1.To elect our two nominees for Class II directors to hold office until the 2026 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement accompanying this Notice.
3.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
4.To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers.
|
| 2022-04-14 |
股东大会：
将于2022-05-26召开股东大会
会议内容 ▼▲
- 1.To elect our five nominees for Class I directors to hold office until the 2025 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve the amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 15,000,000.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement accompanying this Notice.
4.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-16 |
股东大会：
将于2021-05-28召开股东大会
会议内容 ▼▲
- 1.To elect our three nominees for Class III directors to hold office until the 2024 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve the amendment and restatement of the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 1,000,000.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
4.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
5.To conduct any other business properly brought before the meeting or any adjournment(s) thereof.
|
| 2020-05-29 |
复牌提示：
2020-05-29 10:33:01 停牌，复牌日期 2020-05-29 10:38:01
|
| 2020-04-17 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect our three nominees for Class II directors to hold office until the 2023 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve an amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 139,000,000 to 278,000,000.
3.To approve an amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan (the “2018 EIP”) to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2018 EIP by 7,600,000.
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
5.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
6.To conduct any other business properly brought before the meeting or any adjournment(s) thereof.
|
| 2019-04-22 |
股东大会：
将于2019-05-30召开股东大会
会议内容 ▼▲
- 1.To elect our nominees for Class I directors to hold office until the 2022 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve an amendment and restatement of the Dynavax Technologies Corporation 2018 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 2,300,000.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
4.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
5.To conduct any other business properly brought before the meeting or any adjournment(s) thereof.
|
| 2018-04-20 |
股东大会：
将于2018-05-31召开股东大会
会议内容 ▼▲
- 1.To elect our nominees for Class III directors to hold office until the 2021 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To approve the Dynavax Technologies Corporation 2018 Equity Incentive Plan.
3.To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 600,000.
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
5.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.
6.To conduct any other business properly brought before the meeting or any adjournment(s) thereof.
|
| 2017-07-10 |
股东大会：
将于2017-07-31召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 69,500,000 to 139,000,000.
2.To authorize an adjournment of the meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Proposal 1
3.To transact any other business that may be properly brought before the meeting or any continuation, adjournment or postponement thereof.
|
| 2017-04-21 |
股东大会：
将于2017-05-31召开股东大会
会议内容 ▼▲
- 1.To elect our nominees for Class II directors to hold office until the 2020 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To amend and restate the Dynavax Technologies Corporation 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 1,600,000.
3.To approve an amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 69,500,000 to 139,000,000.
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
5.To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers.
6.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017.
7.To conduct any other business properly brought before the meeting or any adjournment(s) thereof.
|
| 2016-04-22 |
股东大会：
将于2016-05-31召开股东大会
会议内容 ▼▲
- 1.To elect our nominees for Class I directors to hold office until the 2019 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified.
2.To amend and restate the Dynavax Technologies Corporation 2011 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 3,200,000, and to approve the award limits and other terms applicable to awards intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code.
3.To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 200,000.
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
5.To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.
6.To conduct any other business properly brought before the meeting or any adjournment(s) thereof.
|